TY  - GEN 
AU  - De La Cruz Ojeda, Patricia
AU  - Praena Fernández, Juan Manuel
PY  - 2022
UR  - https://hdl.handle.net/10481/77030
AB  - Background: Sorafenib constitutes a suitable treatment alternative for patients with advanced
hepatocellular carcinoma (HCC) in whom atezolizumab + bevacizumab therapy is contraindicated.
The aim of the study was the identification of a miRNA...
LA  - eng
PB  - MDPI
KW  - Extracellular vesicle
KW  - Hepatocellular carcinoma
KW  - miRNA
KW  - Liquid biopsy
KW  - Sorafenib
TI  - miR-200c-3p, miR-222-5p, and miR-512-3p Constitute a Biomarker Signature of Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
DO  - 10.3390/cells11172673
ER  -